{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:43:45Z","timestamp":1793472225203,"version":"4.5.0"},"reference-count":298,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430123"],"award-info":[{"award-number":["82430123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023LZY006"],"award-info":[{"award-number":["ZR2023LZY006"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"National Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.canlet.2026.218321","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:04:02Z","timestamp":1771488242000},"page":"218321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer"],"prefix":"10.1016","volume":"644","author":[{"given":"Jingyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minpu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chundi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-8788","authenticated-orcid":false,"given":"Changgang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-0956","authenticated-orcid":false,"given":"Jing","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-024-01998-w","article-title":"circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p\/IGF1R pathway in non-small cell lung cancer (NSCLC)","volume":"23","author":"Tang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"23","key":"10.1016\/j.canlet.2026.218321_bib2","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1097\/CM9.0000000000002548","article-title":"Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.canlet.2026.218321_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.canlet.2018.02.004","article-title":"Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies","volume":"420","author":"Tang","year":"2018","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.694","article-title":"Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies","volume":"5","author":"Ou","year":"2020","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mco2.105","article-title":"Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy","volume":"2","author":"Cheng","year":"2020","journal-title":"MedComm"},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib9","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2018.05.024","article-title":"EGFR L792H and G796R: two novel mutations mediating resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib","volume":"13","author":"Zhang","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"18","key":"10.1016\/j.canlet.2026.218321_bib10","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","article-title":"Tackling osimertinib resistance in EGFR-mutant non-small cell lung cancer","volume":"29","author":"Blaquier","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218321_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218321_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.05.006","article-title":"Current knowledge of small cell lung cancer transformation from non-small cell lung cancer","volume":"94","author":"Giaccone","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218321_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2018.09.007","article-title":"Hybrid epithelial\/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas","volume":"194","author":"Jolly","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib14","article-title":"Itraconazole reversing acquired resistance to osimertinib in NSCLC by inhibiting the SHH\/DUSP13B\/p-STAT3 axis","volume":"12","author":"Zheng","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218321_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216762","article-title":"Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer","volume":"588","author":"Han","year":"2024","journal-title":"Cancer Lett."},{"issue":"13","key":"10.1016\/j.canlet.2026.218321_bib16","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218321_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.03123","article-title":"Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review","author":"Piper-Vallillo","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-025-02285-y","article-title":"NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer","volume":"24","author":"Dai","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102091","article-title":"miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44","volume":"35","author":"Wu","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104321","article-title":"Epigenetic code underlying EGFR-TKI resistance in non-small cell lung cancer: elucidation of mechanisms and perspectives on therapeutic strategies","volume":"30","author":"Yao","year":"2025","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-23-0530","article-title":"Cancer evolution: a multifaceted affair","volume":"14","author":"Ciriello","year":"2024","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s12276-023-01014-z","article-title":"Histone modifications in drug-resistant cancers: from a cancer stem cell and immune evasion perspective","volume":"55","author":"Jin","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218321_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.semcancer.2020.12.022","article-title":"Targeting epigenetic regulatory machinery to overcome cancer therapy resistance","volume":"83","author":"Guo","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cac2.12374","article-title":"Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities","volume":"42","author":"Ge","year":"2022","journal-title":"Cancer Commun."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib26","first-page":"277","article-title":"The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy","volume":"2","author":"Yang","year":"2022","journal-title":"J. Natl. Cancer Cent."},{"issue":"14","key":"10.1016\/j.canlet.2026.218321_bib27","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.7150\/thno.42523","article-title":"Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer","volume":"10","author":"Ravindran Menon","year":"2020","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.342","article-title":"Targeting drug-tolerant cells: a promising strategy for overcoming acquired drug resistance in cancer cells","volume":"4","author":"Song","year":"2020","journal-title":"MedComm"},{"issue":"8022","key":"10.1016\/j.canlet.2026.218321_bib29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Fran\u00e7a","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.trecan.2021.01.009","article-title":"Group behavior and emergence of cancer drug resistance","volume":"7","author":"Bhattacharya","year":"2021","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib31","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41419-025-07711-z","article-title":"Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer","volume":"16","author":"Dayanc","year":"2025","journal-title":"Cell Death Dis."},{"issue":"14","key":"10.1016\/j.canlet.2026.218321_bib33","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1158\/0008-5472.CAN-21-3844","article-title":"Drug-tolerant persister cells in cancer therapy resistance","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib34","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114903","article-title":"Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy","volume":"14","author":"Zhang","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"Pt 2","key":"10.1016\/j.canlet.2026.218321_bib35","article-title":"CRISPR\/Cas-mediated macromolecular DNA methylation editing: precision targeting of DNA methyltransferases in cancer therapy","volume":"308","author":"Chen","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.canlet.2026.218321_bib36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.actbio.2025.03.032","article-title":"Effective delivery of CRISPR\/dCas9-SAM for multiplex gene activation based on mesoporous silica nanoparticles for bladder cancer therapy","volume":"197","author":"Xu","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.canlet.2026.218321_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1499301","article-title":"Spatial transcriptomics in breast cancer: providing insight into tumor heterogeneity and promoting individualized therapy","volume":"15","author":"An","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40265-022-01698-z","article-title":"Targeting acquired and intrinsic resistance mechanisms in epidermal growth factor receptor mutant non-small-cell lung cancer","volume":"82","author":"Shah","year":"2022","journal-title":"Drugs"},{"issue":"28","key":"10.1016\/j.canlet.2026.218321_bib39","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1038\/s41388-019-0814-6","article-title":"JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells","volume":"38","author":"Duan","year":"2019","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib40","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1093\/nar\/gkab280","article-title":"Histone sumoylation and chromatin dynamics","volume":"49","author":"Ryu","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"16","key":"10.1016\/j.canlet.2026.218321_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg6593","article-title":"Epigenetic moonlighting: catalytic-independent functions of histone modifiers in regulating transcription","volume":"9","author":"Morgan","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib42","doi-asserted-by":"crossref","first-page":"9614","DOI":"10.1038\/s41467-024-53981-0","article-title":"The BAF complex enhances transcription through interaction with H3K56ac in the histone globular domain","volume":"15","author":"Hyun","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib43","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1093\/nar\/gkae361","article-title":"asteRIa enables robust interaction modeling between chromatin modifications and epigenetic readers","volume":"52","author":"Stadler","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.canlet.2026.218321_bib44","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1021\/acs.accounts.1c00463","article-title":"Integrative chemical biology approaches to deciphering the histone code: a problem-driven journey","volume":"54","author":"Li","year":"2021","journal-title":"Acc. Chem. Res."},{"issue":"D1","key":"10.1016\/j.canlet.2026.218321_bib45","first-page":"D264","article-title":"WERAM: a database of writers, erasers and readers of histone acetylation and methylation in eukaryotes","volume":"45","author":"Xu","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib46","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1038\/s41467-024-48698-z","article-title":"Active transcription and epigenetic reactions synergistically regulate meso-scale genomic organization","volume":"15","author":"Kant","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib47","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1038\/s41467-022-32911-y","article-title":"Regulation associated modules reflect 3D genome modularity associated with chromatin activity","volume":"13","author":"Zheng","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2016.06.038","article-title":"Diverse activities of histone acylations connect metabolism to chromatin function","volume":"63","author":"Dutta","year":"2016","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib49","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.molcel.2021.01.041","article-title":"A unique histone 3 lysine 14 chromatin signature underlies tissue-specific gene regulation","volume":"81","author":"Regadas","year":"2021","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41588-022-01260-3","article-title":"Single-cell sortChIC identifies hierarchical chromatin dynamics during hematopoiesis","volume":"55","author":"Zeller","year":"2023","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41588-022-01026-x","article-title":"Prediction of histone post-translational modification patterns based on nascent transcription data","volume":"54","author":"Wang","year":"2022","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib52","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer","volume":"41","author":"de Miguel","year":"2023","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.canlet.2026.218321_bib53","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-17-3146","article-title":"Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors","volume":"78","author":"Yun","year":"2018","journal-title":"Cancer Res."},{"issue":"43","key":"10.1016\/j.canlet.2026.218321_bib54","article-title":"EGFR targeted liposomal PROTAC assisted with epigenetic regulation as an efficient strategy for osimertinib-resistant lung cancer therapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib55","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/0008-5472.CAN-20-0821","article-title":"Loss of KMT5C promotes EGFR inhibitor resistance in NSCLC via LINC01510-Mediated upregulation of MET","volume":"82","author":"Pal","year":"2022","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.canlet.2026.218321_bib56","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1158\/0008-5472.CAN-17-0072","article-title":"HDAC1 upregulation by NANOG promotes multidrug resistance and a stem-like phenotype in immune edited tumor cells","volume":"77","author":"Song","year":"2017","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147908","article-title":"Targeting the NANOG\/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle","volume":"132","author":"Oh","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218321_bib58","article-title":"Co-activation of super-enhancer complex SOX2 and HDAC1 confers temozolomide resistance by promoting PDGFB transcription in glioblastoma","author":"Xie","year":"2025","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib59","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/bloodadvances.2022007155","article-title":"Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase","volume":"7","author":"Harada","year":"2023","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add3243","article-title":"HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer","volume":"9","author":"Eichner","year":"2023","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41416-022-01805-7","article-title":"HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3","volume":"127","author":"Zang","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-022-01662-1","article-title":"Costunolide is a dual inhibitor of MEK1 and AKT1\/2 that overcomes osimertinib resistance in lung cancer","volume":"21","author":"Tian","year":"2022","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108744","article-title":"An acetyl-histone vulnerability in PI3K\/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors","volume":"34","author":"Wu","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbcan.2017.03.002","article-title":"The emerging role of PI3K\/AKT-mediated epigenetic regulation in cancer","volume":"1868","author":"Spangle","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"12","key":"10.1016\/j.canlet.2026.218321_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115015","article-title":"Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma","volume":"43","author":"Wang","year":"2024","journal-title":"Cell Rep."},{"issue":"7-8","key":"10.1016\/j.canlet.2026.218321_bib66","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1101\/gad.311027.117","article-title":"Acetyl-CoA promotes glioblastoma cell adhesion and migration through Ca(2+)-NFAT signaling","volume":"32","author":"Lee","year":"2018","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib67","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.32744","article-title":"Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)","volume":"126","author":"Zang","year":"2020","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.canlet.2026.218321_bib68","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1158\/1078-0432.CCR-16-2271","article-title":"Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-Mutant lung cancer","volume":"23","author":"Tanimoto","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib69","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.7150\/thno.54824","article-title":"Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"issue":"20","key":"10.1016\/j.canlet.2026.218321_bib70","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145035","article-title":"Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tips.2017.11.008","article-title":"Combination therapies targeting HDAC and IKK in solid tumors","volume":"39","author":"Vancurova","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"21","key":"10.1016\/j.canlet.2026.218321_bib72","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib73","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2020.03.005","article-title":"KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer","volume":"37","author":"Alam","year":"2020","journal-title":"Cancer Cell"},{"issue":"7846","key":"10.1016\/j.canlet.2026.218321_bib74","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-020-03170-y","article-title":"Elevated NSD3 histone methylation activity drives squamous cell lung cancer","volume":"590","author":"Yuan","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib75","article-title":"Histone methyltransferase NSD3 is a lung squamous cell carcinoma driver","volume":"11","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218321_bib76","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.omtn.2021.12.032","article-title":"CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma","volume":"27","author":"Hu","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"14","key":"10.1016\/j.canlet.2026.218321_bib77","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/0008-5472.CAN-17-3571","article-title":"HP1\u03b3 promotes lung adenocarcinoma by downregulating the transcription-repressive regulators NCOR2 and ZBTB7A","volume":"78","author":"Alam","year":"2018","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib78","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jtho.2020.03.023","article-title":"Genome-Wide DNA methylation profiling in early stage I lung adenocarcinoma reveals predictive aberrant methylation in the promoter region of the long noncoding RNA PLUT: an exploratory study","volume":"15","author":"Kim-Wanner","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib79","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41419-023-05840-x","article-title":"LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer","volume":"14","author":"Dai","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib80","doi-asserted-by":"crossref","first-page":"6755","DOI":"10.1038\/s41467-024-50861-5","article-title":"Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia\/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218321_bib81","article-title":"Enhancer extrachromosomal circular DNA ANKRD28 elicits drug resistance via POU2F2-Mediated transcriptional network in multiple myeloma","author":"Chen","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib82","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41388-018-0429-3","article-title":"Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer","volume":"38","author":"Kim","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218321_bib83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2020.09.003","article-title":"Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"495","author":"Quan","year":"2020","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113714","article-title":"EZH2\/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4\/ERK\/c-Myc signaling axis","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep."},{"issue":"13-14","key":"10.1016\/j.canlet.2026.218321_bib85","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1101\/gad.337592.120","article-title":"A disproportionate impact of G9a methyltransferase deficiency on the X chromosome","volume":"35","author":"Szanto","year":"2021","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib86","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/0008-5472.CAN-21-2218","article-title":"Combined inhibition of G9a and EZH2 suppresses tumor growth via synergistic induction of IL24-Mediated apoptosis","volume":"82","author":"Casciello","year":"2022","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106994","article-title":"SMYD3 induces sorafenib resistance by activating SMAD2\/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib88","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jgg.2016.05.008","article-title":"Epigenetic modulations rendering cell-to-cell variability and phenotypic metastability","volume":"43","author":"Spencer","year":"2016","journal-title":"J. Genet. Genomics"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib89","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-021-01186-z","article-title":"Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation","volume":"14","author":"Quintanal-Villalonga","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib90","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/brv.12416","article-title":"Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer","volume":"93","author":"Bronte","year":"2018","journal-title":"Biol. Rev. Camb. Phil. Soc."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib91","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12916-024-03389-w","article-title":"Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer","volume":"22","author":"Han","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2026.218321_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102824","article-title":"Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development","volume":"130","author":"Corvaja","year":"2024","journal-title":"Cancer Treat Rev."},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218321_bib94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40364-019-0179-6","article-title":"Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"Biomark. Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib95","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jtho.2020.01.027","article-title":"Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET Exon 14 skipping mutations","volume":"15","author":"Jamme","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib96","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41388-019-1099-5","article-title":"Targeting the IL-1\u03b2\/EHD1\/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC","volume":"39","author":"Huang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218321_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217124","article-title":"Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer","volume":"598","author":"Nakamura","year":"2024","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib98","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1078-0432.CCR-23-0163","article-title":"Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable","volume":"30","author":"Codilupi","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib99","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1101\/gr.276313.121","article-title":"MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites","volume":"32","author":"See","year":"2022","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13058-025-02006-9","article-title":"Histone acetylation modulators in breast cancer","volume":"27","author":"Yuan","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2026.218321_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122639","article-title":"Deciphering the interplay of histone post-translational modifications in cancer: Co-targeting histone modulators for precision therapy","volume":"346","author":"Kawaf","year":"2024","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib102","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw283","article-title":"The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion","volume":"109","author":"Lu","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"22","key":"10.1016\/j.canlet.2026.218321_bib103","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2024013699","article-title":"Increased CCL2\/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC\/BCL2 double-expressor DLBCL","volume":"8","author":"Kim","year":"2024","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib104","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41419-022-05169-x","article-title":"Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib105","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/s41467-019-12384-2","article-title":"Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24","volume":"10","author":"Yu","year":"2019","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.canlet.2026.218321_bib106","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-22-1270","article-title":"The HDAC2-SP1 axis orchestrates protumor macrophage polarization","volume":"83","author":"Zheng","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218321_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104200","article-title":"Blockade of STAT3\/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization","volume":"83","author":"Sun","year":"2022","journal-title":"EBioMedicine"},{"issue":"21-22","key":"10.1016\/j.canlet.2026.218321_bib108","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1101\/gad.343038.120","article-title":"The transcription factor EGR2 is the molecular linchpin connecting STAT6 activation to the late, stable epigenomic program of alternative macrophage polarization","volume":"34","author":"Daniel","year":"2020","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib109","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s44320-025-00141-1","article-title":"Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures","volume":"21","author":"Hsu","year":"2025","journal-title":"Mol. Syst. Biol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib110","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1158\/0008-5472.CAN-24-0274","article-title":"A path to persistence after EGFR inhibition","volume":"84","author":"Rumde","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib111","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","article-title":"Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure","volume":"32","author":"Guler","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib112","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41419-025-07498-z","article-title":"Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis","volume":"16","author":"Deng","year":"2025","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib113","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-17-1904","article-title":"ER stress signaling promotes the survival of cancer \"Persister Cells\" tolerant to EGFR tyrosine kinase inhibitors","volume":"78","author":"Terai","year":"2018","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.canlet.2026.218321_bib114","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1007\/s00018-016-2303-1","article-title":"Epigenetic regulation of epithelial-mesenchymal transition","volume":"73","author":"Sun","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib115","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s42003-024-06441-w","article-title":"Regulating epithelial-mesenchymal plasticity from 3D genome organization","volume":"7","author":"Pang","year":"2024","journal-title":"Commun. Biol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib116","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41419-024-07011-y","article-title":"EZH2 represses mesenchymal genes and upholds the epithelial state of breast carcinoma cells","volume":"15","author":"Gallardo","year":"2024","journal-title":"Cell Death Dis."},{"issue":"14","key":"10.1016\/j.canlet.2026.218321_bib117","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/onc.2016.358","article-title":"ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis","volume":"36","author":"Peng","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218321_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1444923","article-title":"The modification role and tumor association with a methyltransferase: KMT2C","volume":"15","author":"Jiao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218321_bib119","article-title":"A genetic cell context-dependent role for ZEB1 in lung cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218321_bib120","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/scitranslmed.aaq1238","article-title":"ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism","volume":"11","author":"Peng","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"20","key":"10.1016\/j.canlet.2026.218321_bib121","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1111\/bph.13961","article-title":"Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo","volume":"174","author":"Yu","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib122","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.gendis.2023.02.006","article-title":"PRMT1 promotes the proliferation and metastasis of gastric cancer cells by recruiting MLXIP for the transcriptional activation of the \u03b2-catenin pathway","volume":"10","author":"Wang","year":"2023","journal-title":"Genes Dis."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib123","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41419-019-1595-0","article-title":"PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation","volume":"10","author":"Zhao","year":"2019","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib124","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41388-024-03220-z","article-title":"RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1","volume":"44","author":"Li","year":"2025","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib125","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1158\/0008-5472.CAN-16-2609","article-title":"miRNA-520f reverses epithelial-to-mesenchymal transition by targeting ADAM9 and TGFBR2","volume":"77","author":"van Kampen","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib126","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-018-0988-8","article-title":"Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors","volume":"37","author":"Su","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9070072","article-title":"Epigenetic regulation of the epithelial to mesenchymal transition in lung cancer","volume":"9","author":"Roche","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.canlet.2026.218321_bib128","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-21-0556","article-title":"Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third-generation EGFR tyrosine kinase inhibitor","volume":"81","author":"Zhu","year":"2021","journal-title":"Osimertinib. Cancer Res."},{"issue":"12","key":"10.1016\/j.canlet.2026.218321_bib129","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/2159-8290.CD-20-1863","article-title":"Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation","volume":"11","author":"Quintanal-Villalonga","year":"2021","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.molcel.2020.10.033","article-title":"Impact of lineage plasticity to and from a neuroendocrine phenotype on progression and response in prostate and lung cancers","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib131","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218321_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103044","article-title":"Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming","volume":"141","author":"Wang","year":"2025","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib133","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41392-024-01981-3","article-title":"Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"26","key":"10.1016\/j.canlet.2026.218321_bib134","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","article-title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib135","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","article-title":"Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-Aberrant solid tumors","volume":"175","author":"Huang","year":"2018","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.canlet.2026.218321_bib136","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41419-024-07155-x","article-title":"VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib137","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2022.09.018","article-title":"Squamous cell lung cancer: current landscape and future therapeutic options","volume":"40","author":"Lau","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib138","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-022-01586-w","article-title":"The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p\/CARM1 axis","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib139","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13059-021-02376-1","article-title":"A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks","volume":"22","author":"Yuan","year":"2021","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40880-019-0376-6","article-title":"PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer","volume":"39","author":"Larsen","year":"2019","journal-title":"Cancer Commun."},{"issue":"21","key":"10.1016\/j.canlet.2026.218321_bib141","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1158\/0008-5472.CAN-23-2922","article-title":"Epigenetic regulators open the door to SCLC plasticity","volume":"83","author":"Weber","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218321_bib142","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2020.11.006","article-title":"Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease","volume":"83","author":"Khan","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib143","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jtho.2018.11.021","article-title":"EGFR-Mutant SCLC exhibits heterogeneous phenotypes and resistance to common antineoplastic drugs","volume":"14","author":"Lin","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib144","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41556-023-01210-z","article-title":"KDM6A epigenetically regulates subtype plasticity in small cell lung cancer","volume":"25","author":"Duplaquet","year":"2023","journal-title":"Nat. Cell Biol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib145","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jtho.2018.07.096","article-title":"An integrative analysis of transcriptome and epigenome features of ASCL1-Positive lung adenocarcinomas","volume":"13","author":"Miyashita","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.canlet.2026.218321_bib146","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1158\/0008-5472.CAN-21-3713","article-title":"Inhibition of Karyopherin \u03b21-Mediated nuclear import disrupts oncogenic lineage-defining transcription factor activity in small cell lung cancer","volume":"82","author":"Kelenis","year":"2022","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib147","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccell.2017.01.013","article-title":"Awakening of \"Schlafen11\" to tackle chemotherapy resistance in SCLC","volume":"31","author":"Berns","year":"2017","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.canlet.2026.218321_bib148","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202500162","article-title":"A method for constructing Nucleosome arrays with spatially defined histone PTMs and DNA damage","volume":"64","author":"Liu","year":"2025","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"15","key":"10.1016\/j.canlet.2026.218321_bib149","article-title":"Yeast bromodomain factor 1 and its human homolog TAF1 play conserved roles in promoting homologous recombination","volume":"8","author":"Peng","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib150","first-page":"1159","article-title":"Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan","volume":"45","author":"Meisenberg","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib151","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41419-024-06796-2","article-title":"L3MBTL1, a polycomb protein, promotes Osimertinib acquired resistance through epigenetic regulation of DNA damage response in lung adenocarcinoma","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib152","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11427-024-2543-9","article-title":"Di- and tri-methylation of histone H3K36 play distinct roles in DNA double-strand break repair","volume":"67","author":"Chen","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.canlet.2026.218321_bib153","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13578-020-0374-z","article-title":"H3K36me3, message from chromatin to DNA damage repair","volume":"10","author":"Sun","year":"2020","journal-title":"Cell Biosci."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib154","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00401-022-02489-2","article-title":"Oncohistone interactome profiling uncovers contrasting oncogenic mechanisms and identifies potential therapeutic targets in high grade glioma","volume":"144","author":"Siddaway","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib155","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41401-020-00577-1","article-title":"Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer","volume":"42","author":"Liang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2026.218321_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216365","article-title":"Circulating tumor DNA as liquid biopsy in lung cancer: biological characteristics and clinical integration","volume":"577","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"28","key":"10.1016\/j.canlet.2026.218321_bib157","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between Plasma Genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s44276-025-00129-2","article-title":"Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance","volume":"3","author":"Ingham","year":"2025","journal-title":"BJC Rep."},{"key":"10.1016\/j.canlet.2026.218321_bib159","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18591","article-title":"RYBP stimulates PRC1 to shape chromatin-based communication between Polycomb repressive complexes","volume":"5","author":"Rose","year":"2016","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/cells12030374","article-title":"Defining a correlative transcriptional signature associated with bulk histone H3 acetylation levels in adult glioblastomas","volume":"12","author":"Herv\u00e1s-Corpi\u00f3n","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib161","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70080","article-title":"Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis","volume":"6","author":"Bi","year":"2020","journal-title":"MedComm"},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib162","article-title":"The spatial multi-omics revolution in cancer therapy: precision redefined","volume":"5","author":"Du","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218321_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117218","article-title":"Small molecules targeting HDAC6 for cancer treatment: current progress and novel strategies","volume":"178","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202407245","article-title":"Less is more: biomimetic hybrid membrane nanocarriers for highly efficient tumor targeted drug delivery","volume":"21","author":"Chen","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.canlet.2026.218321_bib165","doi-asserted-by":"crossref","first-page":"10623","DOI":"10.2147\/IJN.S480095","article-title":"The advances in the development of epigenetic modifications therapeutic drugs delivery systems","volume":"19","author":"Li","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib166","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s12276-024-01221-2","article-title":"Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer","volume":"56","author":"Park","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218321_bib167","doi-asserted-by":"crossref","DOI":"10.1111\/cas.70032","article-title":"Novel approach to overcome osimertinib resistance using bromodomain and extra-terminal domain inhibitors","author":"Miyashita","year":"2025","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib168","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jhep.2023.05.031","article-title":"Identification and experimental validation of druggable epigenetic targets in hepatoblastoma","volume":"79","author":"Claver\u00eda-Cabello","year":"2023","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib169","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2159-8290.CD-22-0692","article-title":"Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes","volume":"13","author":"De Sarkar","year":"2023","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41418-023-01213-1","article-title":"Mapping epigenetic modifications by sequencing technologies","volume":"32","author":"Chen","year":"2025","journal-title":"Cell Death Differ."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib171","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jtho.2024.07.008","article-title":"Longitudinal analyses of circulating tumor DNA for the detection of EGFR mutation-positive advanced NSCLC progression during treatment: data from FLAURA and AURA3","volume":"19","author":"Gray","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib172","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges","volume":"5","author":"Li","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218321_bib173","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib174","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41587-020-00775-6","article-title":"ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin","volume":"39","author":"Sadeh","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218321_bib175","article-title":"Urine cf-nucleosomes: a non-invasive window into human physiology and disease","volume":"5","author":"Lotem","year":"2025","journal-title":"Cell Genom."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib176","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrg.2017.117","article-title":"Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations","volume":"19","author":"Salk","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib177","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ccell.2016.03.009","article-title":"Intratumoral heterogeneity of the epigenome","volume":"29","author":"Mazor","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218321_bib178","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semcancer.2020.12.011","article-title":"Use of DNA methylation profiling in translational oncology","volume":"83","author":"Ortiz-Barahona","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"21","key":"10.1016\/j.canlet.2026.218321_bib179","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1016\/j.molcel.2021.08.034","article-title":"NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis","volume":"81","author":"Sengupta","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218321_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218010","article-title":"Targeting MKK3\/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer","volume":"633","author":"Chen","year":"2025","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib181","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.chest.2020.01.048","article-title":"Independent validation of early-stage non-small cell lung cancer Prognostic scores incorporating epigenetic and transcriptional biomarkers with gene-gene interactions and main effects","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.canlet.2026.218321_bib182","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2016.77","article-title":"Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array","volume":"3","author":"Partolina","year":"2017","journal-title":"Cell Death Discov."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib183","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.neo.2019.03.012","article-title":"Global reduction of H3K4me3 improves chemotherapeutic efficacy for pediatric ependymomas","volume":"21","author":"Lewis","year":"2019","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib184","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-016-1133-7","article-title":"Single-cell epigenomic variability reveals functional cancer heterogeneity","volume":"18","author":"Litzenburger","year":"2017","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41568-024-00757-9","article-title":"Epigenomic heterogeneity as a source of tumour evolution","volume":"25","author":"Laisn\u00e9","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib186","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13059-024-03446-w","article-title":"EpiCHAOS: a metric to quantify epigenomic heterogeneity in single-cell data","volume":"25","author":"Kelly","year":"2024","journal-title":"Genome Biol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib187","article-title":"Epigenetics: mechanisms, potential roles, and therapeutic strategies in cancer progression","volume":"11","author":"Wang","year":"2024","journal-title":"Genes Dis."},{"issue":"10","key":"10.1016\/j.canlet.2026.218321_bib188","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.trecan.2022.06.005","article-title":"Single cell cancer epigenetics","volume":"8","author":"Casado-Pelaez","year":"2022","journal-title":"Trends Cancer"},{"issue":"19","key":"10.1016\/j.canlet.2026.218321_bib189","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood.2023019758","article-title":"Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis","volume":"142","author":"Poos","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.canlet.2026.218321_bib190","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11122444","article-title":"SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in cancer","volume":"11","author":"Lee","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.canlet.2026.218321_bib191","article-title":"Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"18","key":"10.1016\/j.canlet.2026.218321_bib192","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-20-2811","article-title":"Single-Cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer","volume":"81","author":"Kashima","year":"2021","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib193","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41556-018-0248-3","article-title":"A chromatin integration labelling method enables epigenomic profiling with lower input","volume":"21","author":"Harada","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib194","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13059-019-1854-5","article-title":"Assessment of computational methods for the analysis of single-cell ATAC-seq data","volume":"20","author":"Chen","year":"2019","journal-title":"Genome Biol."},{"issue":"19","key":"10.1016\/j.canlet.2026.218321_bib195","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz716","article-title":"Global prediction of chromatin accessibility using small-cell-number and single-cell RNA-seq","volume":"47","author":"Zhou","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib196","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s42003-023-05601-8","article-title":"Organ-specific characteristics govern the relationship between histone code dynamics and transcriptional reprogramming during nitrogen response in tomato","volume":"6","author":"Julian","year":"2023","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib197","doi-asserted-by":"crossref","DOI":"10.1515\/jib-2023-0012","article-title":"Integrating omics databases for enhanced crop breeding","volume":"20","author":"Chao","year":"2023","journal-title":"J. Integr. Bioinform."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib198","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/0008-5472.CAN-24-0529","article-title":"H4K20me3-Mediated repression of inflammatory genes is a characteristic and targetable vulnerability of persister cancer cells","volume":"85","author":"Ramponi","year":"2025","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib199","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.653","article-title":"Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis","volume":"5","author":"Huang","year":"2020","journal-title":"MedComm"},{"issue":"10","key":"10.1016\/j.canlet.2026.218321_bib200","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1158\/0008-5472.CAN-19-3819","article-title":"Drug sensitivity and Allele specificity of first-line osimertinib resistance EGFR mutations","volume":"80","author":"Starrett","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib201","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1038\/s41467-022-34889-z","article-title":"Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer","volume":"13","author":"Adua","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib202","article-title":"Connecting high-resolution 3D chromatin organization with epigenomics","volume":"13","author":"Feng","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib203","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41587-022-01603-9","article-title":"Solid-phase capture and profiling of open chromatin by spatial ATAC","volume":"41","author":"Llorens-Bobadilla","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.drudis.2021.08.004","article-title":"Vorinostat in autophagic cell death: a critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention","volume":"27","author":"Patra","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib205","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/cas.14260","article-title":"Phase I study of vorinostat with gefitinib in BIM deletion polymorphism\/epidermal growth factor receptor mutation double-positive lung cancer","volume":"111","author":"Takeuchi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218321_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101121","article-title":"Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat","volume":"60","author":"Zenz","year":"2025","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib207","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41401-020-0442-2","article-title":"MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer","volume":"42","author":"Shang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"12","key":"10.1016\/j.canlet.2026.218321_bib208","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41589-018-0150-0","article-title":"Identification of a cellularly active SIRT6 allosteric activator","volume":"14","author":"Huang","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218321_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114677","article-title":"A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells","volume":"194","author":"Lu","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/epi-2023-0142","article-title":"Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements","volume":"15","author":"Singh","year":"2023","journal-title":"Epigenomics"},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib211","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1021\/acschembio.2c00062","article-title":"Exploring methods of targeting histone methyltransferases and their applications in cancer therapeutics","volume":"17","author":"Wang","year":"2022","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib212","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41467-022-29292-7","article-title":"Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer","volume":"13","author":"Gogleva","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib213","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-024-00594-4","article-title":"A cohort-based multi-omics identifies nuclear translocation of eIF5B\/PD-L1\/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma","volume":"14","author":"Sun","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib214","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41416-020-01032-y","article-title":"E2F7-EZH2 axis regulates PTEN\/AKT\/mTOR signalling and glioblastoma progression","volume":"123","author":"Yang","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218321_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102287","article-title":"Targeting ARID1A mutations in cancer","volume":"100","author":"Mullen","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"10","key":"10.1016\/j.canlet.2026.218321_bib216","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.jtho.2025.06.007","article-title":"Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-Mutant lung cancer","volume":"20","author":"Fukuda","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218321_bib217","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1016\/j.jtho.2025.07.118","article-title":"Defining ARID1A-Driven WEE1 vulnerability and clarifying its predictive value in EGFR-Mutant NSCLC-Author's reply","volume":"20","author":"Fukuda","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218321_bib218","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2019.03.027","article-title":"Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer","volume":"452","author":"Li","year":"2019","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib219","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/febs.16656","article-title":"Balance between autophagy and cell death is maintained by Polycomb-mediated regulation during stem cell differentiation","volume":"290","author":"Puri","year":"2023","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib220","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41420-023-01599-4","article-title":"Cezanne promoted autophagy through PIK3C3 stabilization and PIK3C2A transcription in lung adenocarcinoma","volume":"9","author":"Wang","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.canlet.2026.218321_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217587","article-title":"Epigenetic modification and tumor immunity: unraveling the interplay with the tumor microenvironment and its therapeutic vulnerability and implications","volume":"616","author":"Zheng","year":"2025","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib222","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s13167-022-00300-6","article-title":"DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine","volume":"13","author":"Zhang","year":"2022","journal-title":"EPMA J."},{"issue":"10","key":"10.1016\/j.canlet.2026.218321_bib223","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"20","key":"10.1016\/j.canlet.2026.218321_bib224","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1158\/1078-0432.CCR-24-0160","article-title":"Transcriptomic heterogeneity of EGFR-Mutant non-small cell lung cancer evolution toward small-cell lung cancer","volume":"30","author":"Oh","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218321_bib225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1476-4598-10-18","article-title":"Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis","volume":"10","author":"Li","year":"2011","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.canlet.2026.218321_bib226","doi-asserted-by":"crossref","first-page":"9732","DOI":"10.1021\/acs.jmedchem.1c00601","article-title":"Emerging therapeutic potential of SIRT6 modulators","volume":"64","author":"Fiorentino","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2026.218321_bib227","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijbiomac.2022.12.061","article-title":"Fungal antitumor protein D1 is internalized via endocytosis and inhibits non-small cell lung cancer proliferation through MAPK signaling pathway","volume":"227","author":"Zhang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"21","key":"10.1016\/j.canlet.2026.218321_bib228","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1158\/1078-0432.CCR-17-1574","article-title":"Overcoming acquired resistance to AZD9291, A third-generation EGFR inhibitor, through modulation of MEK\/ERK-Dependent bim and Mcl-1 degradation","volume":"23","author":"Shi","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib229","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41392-024-02030-9","article-title":"Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.trsl.2014.03.001","article-title":"Epigenetics of lung cancer","volume":"165","author":"Langevin","year":"2015","journal-title":"Transl. Res."},{"issue":"10","key":"10.1016\/j.canlet.2026.218321_bib231","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-10-2430","article-title":"The dual EGFR\/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models","volume":"71","author":"LaBonte","year":"2011","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218321_bib232","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41419-021-03697-6","article-title":"EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function","volume":"12","author":"Bahl","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib233","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41698-025-00910-z","article-title":"Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma","volume":"9","author":"Zheng","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218321_bib234","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1007\/s13346-021-01088-0","article-title":"Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation","volume":"12","author":"Sawant","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.canlet.2026.218321_bib235","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jconrel.2020.11.028","article-title":"Cell penetrating peptides: a versatile vector for co-delivery of drug and genes in cancer","volume":"330","author":"Khan","year":"2021","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib236","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10710","article-title":"Targeting the epigenome with advanced delivery strategies for epigenetic modulators","volume":"10","author":"Guha","year":"2025","journal-title":"Bioeng. Transl. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib237","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/acs.nanolett.0c03665","article-title":"Integrating epigenetic modulators in nanofibers for synergistic gastric cancer therapy via epigenetic reprogramming","volume":"21","author":"Wang","year":"2021","journal-title":"Nano Lett."},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib238","article-title":"Emerging epigenetic-based nanotechnology for cancer therapy: modulating the tumor microenvironment","volume":"10","author":"Zhang","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib239","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41401-023-01205-4","article-title":"Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages","volume":"45","author":"Lin","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2026.218321_bib240","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semcancer.2020.12.018","article-title":"CRISPR\/Cas mediated epigenome editing for cancer therapy","volume":"83","author":"Ansari","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib241","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2018-213454","article-title":"Gene editing for inflammatory disorders","volume":"78","author":"Ewart","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib242","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41591-025-03508-x","article-title":"A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels","volume":"31","author":"Tremblay","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib243","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1038\/s41467-025-58312-5","article-title":"Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer","volume":"16","author":"Fu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218321_bib244","article-title":"Epigenetic editing: from concept to clinic","author":"Heller","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib245","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/s12276-022-00836-7","article-title":"DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy","volume":"54","author":"Heo","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib246","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1021\/acs.jmedchem.1c01876","article-title":"Design and synthesis of dual EZH2\/BRD4 inhibitors to target solid tumors","volume":"65","author":"Guo","year":"2022","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib247","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/s41587-022-01560-3","article-title":"scChIX-seq infers dynamic relationships between histone modifications in single cells","volume":"41","author":"Yeung","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib248","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/EBC20220038","article-title":"Stochastic population dynamics of cancer stemness and adaptive response to therapies","volume":"66","author":"Jain","year":"2022","journal-title":"Essays Biochem."},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib249","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.7150\/ijbs.72534","article-title":"Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance","volume":"18","author":"Zhang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"23","key":"10.1016\/j.canlet.2026.218321_bib250","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.cell.2022.09.035","article-title":"Spatially resolved epigenomic profiling of single cells in complex tissues","volume":"185","author":"Lu","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib251","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","article-title":"Spatial multi-omics analyses of the tumor immune microenvironment","volume":"29","author":"Hsieh","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib252","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13059-024-03436-y","article-title":"scStateDynamics: deciphering the drug-responsive tumor cell state dynamics by modeling single-cell level expression changes","volume":"25","author":"Guo","year":"2024","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib253","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/s41467-021-22057-8","article-title":"Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers","volume":"12","author":"Vaclova","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib254","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70225","article-title":"Cell-free epigenomes enhanced fragmentomics-based model for early detection of lung cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"12","key":"10.1016\/j.canlet.2026.218321_bib255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002199","article-title":"Base-Position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective Study","volume":"13","author":"P\u00e9cuchet","year":"2016","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib256","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218321_bib257","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117185","article-title":"Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review","volume":"283","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"9-10","key":"10.1016\/j.canlet.2026.218321_bib258","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s12272-023-01467-w","article-title":"Exploring new histone deacetylase 6 inhibitors and their effects on reversing the \u03b1-tubulin deacetylation and cell morphology changes caused by methamphetamine","volume":"46","author":"Gupta","year":"2023","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib259","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1158\/2159-8290.CD-RW2022-087","article-title":"Chemical proteomics reveals MBLAC2 as a major off-target of HDAC inhibitors","volume":"12","year":"2022","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib260","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41589-022-01015-5","article-title":"Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target","volume":"18","author":"Lechner","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"Pt 1","key":"10.1016\/j.canlet.2026.218321_bib261","article-title":"Emerging natural polymer-based architectured nanotherapeutics for the treatment of cancer","volume":"262","author":"Kuna","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"6581","key":"10.1016\/j.canlet.2026.218321_bib262","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1126\/science.abg7216","article-title":"Spatial-CUT&Tag: spatially resolved chromatin modification profiling at the cellular level","volume":"375","author":"Deng","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib263","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13046-023-02606-3","article-title":"Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer","volume":"42","author":"Yu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib264","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib265","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.canlet.2026.218321_bib266","first-page":"50","volume":"6","author":"Qi","year":"2023"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib267","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13073-018-0545-2","article-title":"Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance","volume":"10","author":"Stein-O'Brien","year":"2018","journal-title":"Genome Med."},{"issue":"2","key":"10.1016\/j.canlet.2026.218321_bib268","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218321_bib269","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/0008-5472.CAN-24-2052","article-title":"Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer","volume":"85","author":"Sipola","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218321_bib270","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216815","article-title":"Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer","volume":"588","author":"Kanaoka","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218321_bib271","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.addr.2017.07.007","article-title":"Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors","volume":"119","author":"Ojha","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2026.218321_bib272","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.addr.2017.09.011","article-title":"Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives","volume":"118","author":"Scomparin","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.canlet.2026.218321_bib273","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41587-022-01250-0","article-title":"Characterizing cellular heterogeneity in chromatin state with scCUT&Tag-pro","volume":"40","author":"Zhang","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"23","key":"10.1016\/j.canlet.2026.218321_bib274","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1158\/0008-5472.CAN-24-0249","article-title":"NUAK1-Mediated phosphorylation of NADK mitigates ROS accumulation to promote osimertinib resistance in non-small cell lung carcinoma","volume":"84","author":"Lin","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib275","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12943-025-02493-6","article-title":"IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer","volume":"24","author":"Ibusuki","year":"2025","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2026.218321_bib276","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/nn.3490","article-title":"Saltatory remodeling of Hox chromatin in response to rostrocaudal patterning signals","volume":"16","author":"Mazzoni","year":"2013","journal-title":"Nat. Neurosci."},{"issue":"22","key":"10.1016\/j.canlet.2026.218321_bib277","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl7393","article-title":"DIRECT-NET: an efficient method to discover cis-regulatory elements and construct regulatory networks from single-cell multiomics data","volume":"8","author":"Zhang","year":"2022","journal-title":"Sci. Adv."},{"issue":"7818","key":"10.1016\/j.canlet.2026.218321_bib278","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41586-020-2119-x","article-title":"Spatiotemporal DNA methylome dynamics of the developing mouse fetus","volume":"583","author":"He","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib279","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s12272-020-01257-8","article-title":"CRISPR-mediated promoter de\/methylation technologies for gene regulation","volume":"43","author":"Sung","year":"2020","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"12","key":"10.1016\/j.canlet.2026.218321_bib280","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1093\/nar\/gkw159","article-title":"Repurposing the CRISPR-Cas9 system for targeted DNA methylation","volume":"44","author":"Vojta","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218321_bib281","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s43018-021-00222-8","article-title":"Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment","volume":"2","author":"Gutierrez","year":"2021","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib282","article-title":"CRISPR\/Cas9-directed epigenetic editing in colorectal cancer","volume":"1880","author":"Gupta","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib283","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12929-023-00898-3","article-title":"Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction","volume":"30","author":"Wattanathamsan","year":"2023","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib284","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2318645","article-title":"Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer","volume":"39","author":"Wang","year":"2024","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"46","key":"10.1016\/j.canlet.2026.218321_bib285","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp3687","article-title":"The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy","volume":"10","author":"Kovalovsky","year":"2024","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib286","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-019-0517-0","article-title":"HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics","volume":"7","author":"Laino","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218321_bib287","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114582","article-title":"Design, synthesis, and biological evaluation of bifunctional inhibitors against Hsp90-HDAC6 interplay","volume":"240","author":"Chae","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib288","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2016.06.001","article-title":"HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma","volume":"379","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib289","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","article-title":"Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer","volume":"8","author":"Jacobsen","year":"2017","journal-title":"Nat. Commun."},{"issue":"Pt C","key":"10.1016\/j.canlet.2026.218321_bib290","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.semcdb.2022.09.009","article-title":"Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: new chances for sophisticated drug design and treatment optimization","volume":"154","author":"Biersack","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"issue":"21","key":"10.1016\/j.canlet.2026.218321_bib291","article-title":"Enhancer extrachromosomal circular DNA ANKRD28 elicits drug resistance via POU2F2-Mediated transcriptional network in multiple myeloma","volume":"12","author":"Chen","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib292","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13519","article-title":"Overcoming the H4K20me3 epigenetic barrier improves somatic cell nuclear transfer reprogramming efficiency in mice","volume":"57","author":"Liu","year":"2024","journal-title":"Cell Prolif."},{"issue":"6","key":"10.1016\/j.canlet.2026.218321_bib293","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00754","article-title":"LINE-1 hypomethylation in cell-free DNA of high-grade glioma patients correlates with tissue levels and is associated with reduced DNMT1 and H4K20me3 expression","volume":"22","author":"Giannopoulou","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.canlet.2026.218321_bib294","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218321_bib295","article-title":"Integrating circulating tumor DNA dynamics and sequential organoid drug screening enhances breast cancer treatment efficacy","author":"Liu","year":"2025","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.canlet.2026.218321_bib296","doi-asserted-by":"crossref","first-page":"eaba1362","DOI":"10.1126\/sciadv.aba1362","article-title":"A multistage assembly\/disassembly strategy for tumor-targeted CO delivery","volume":"6","author":"Meng","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218321_bib297","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.12.011","article-title":"pH-sensitive multi-drug liposomes targeting folate receptor \u03b2 for efficient treatment of non-small cell lung cancer","volume":"330","author":"Park","year":"2021","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.canlet.2026.218321_bib298","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13046-025-03385-9","article-title":"Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy","volume":"44","author":"Ta\u015f","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:08:36Z","timestamp":1777550916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":298,"alternative-id":["S0304383526000844"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218321","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218321"}}